Trial Details
Trial status:
Closed
Recruitment start date:
05/12/2007
Funder:
Leukaemia Research Fund
Sponsor:
UCL
Chief Investigator:
Andrew McMillan
Recruitment target:
N/A
EudraCT number:
2005-003479-19
Contact details:
CTC.Rcodox@ucl.ac.uk
Lay summary:
R-CODOX-M/IVAC (aka RCM)
R-CODOX-M/IVAC: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt’s Lymphoma (BL) of International Prognostic Index (IPI) High or High I
Description
Design:
Treatment:
Key inclusion/exclusion criteria:
Duration of recruitment:
Aim

Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
NameVersionCurrent versRelease dateDownload
Protocol v8.2 8.2 Current
Trial documents
NameTypeVersionCurrent versRelease dateDownload
R-CODOX-M/IVAC Burkitt's lymphoma paperOtherN/A Current 12/03/2020
R-CODOX-M/IVAC DLBCL paperOtherN/A Current 26/05/2020
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2022 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us